Você está no menu de acessibilidade

Utilize este identificador para citar ou criar um link para este item: http://acervodigital.unesp.br/handle/11449/68433
Registro de metadados completo
Campo DCValorIdioma
dc.contributor.authorTávora de Albuquerque Silva, Antonio-
dc.contributor.authorChin, Chung Man-
dc.contributor.authorCastro, Lúcia Fioravanti-
dc.contributor.authorCarvalho Güido, Rafael Victorio-
dc.contributor.authorFerreira, Elizabeth Igne-
dc.date.accessioned2014-05-27T11:21:38Z-
dc.date.accessioned2016-10-25T18:21:10Z-
dc.date.available2014-05-27T11:21:38Z-
dc.date.available2016-10-25T18:21:10Z-
dc.date.issued2005-10-01-
dc.identifierhttp://dx.doi.org/10.2174/138955705774329528-
dc.identifier.citationMini-Reviews in Medicinal Chemistry, v. 5, n. 10, p. 893-914, 2005.-
dc.identifier.issn1389-5575-
dc.identifier.urihttp://hdl.handle.net/11449/68433-
dc.identifier.urihttp://acervodigital.unesp.br/handle/11449/68433-
dc.description.abstractThe background of prodrug design is presented herein as the basis for introducing new and advanced latent systems, taking into account mainly the versatility of polymers and other macromolecules as carriers. PDEPT (Polymer-Directed Enzyme Prodrug Therapy); PELT (Polymer-Enzyme Liposome Therapy); CDS (Chemical Delivery System); ADEPT(Antibody-Directed Enzyme Prodrug Therapy); GDEPT/VDEPT (Gene-Directed Enzyme Prodrug Therapy/Virus-Directed Enzyme Prodrug Therapy); ODDS (Osteotropic Drug Delivery System) and LEAPT (Lectin-directed enzyme-activated prodrug therapy) are briefly described and some examples are given. © 2005 Bentham Science Publishers Ltd.en
dc.format.extent893-914-
dc.language.isoeng-
dc.sourceScopus-
dc.subjectLatent advanced systems-
dc.subjectMacromolecules carriers-
dc.subjectProdrug design-
dc.subjectSelective delivery systems-
dc.subjectaminosalicylic acid-
dc.subjectampicillin-
dc.subjectantiinflammatory agent-
dc.subjectantileishmanial agent-
dc.subjectantimalarial agent-
dc.subjectantineoplastic agent-
dc.subjectbisphosphonic acid derivative-
dc.subjectcytochrome P450-
dc.subjectdiclofenac-
dc.subjectdoxorubicin-
dc.subjectflucytosine-
dc.subjectibuprofen-
dc.subjectirinotecan-
dc.subjectisoniazid-
dc.subjectketoprofen-
dc.subjectmevinolin-
dc.subjectmitomycin-
dc.subjectnitrofural-
dc.subjectpaclitaxel derivative-
dc.subjectphotosensitizing agent-
dc.subjectprodrug-
dc.subjectsalazosulfapyridine-
dc.subjecttacrolimus-
dc.subjecttestosterone derivative-
dc.subjecttiaprofenic acid-
dc.subjecttolmetin-
dc.subjecttrigonelline-
dc.subjecttryptamine derivative-
dc.subjectunindexed drug-
dc.subjectantibody directed enzyme prodrug therapy-
dc.subjectbactericidal activity-
dc.subjectbinding affinity-
dc.subjectblood brain barrier-
dc.subjectChagas disease-
dc.subjectdiarrhea-
dc.subjectdrug absorption-
dc.subjectdrug activation-
dc.subjectdrug design-
dc.subjectdrug distribution-
dc.subjectdrug identification-
dc.subjectdrug receptor binding-
dc.subjectdrug screening-
dc.subjectdrug selectivity-
dc.subjectdrug stability-
dc.subjectdrug structure-
dc.subjectdrug synthesis-
dc.subjectdrug targeting-
dc.subjectdrug transformation-
dc.subjectgastrointestinal toxicity-
dc.subjectgene expression-
dc.subjecthuman-
dc.subjecthypercholesterolemia-
dc.subjectin vivo study-
dc.subjectmacromolecule-
dc.subjectmalaria-
dc.subjectminimum inhibitory concentration-
dc.subjectnephrotoxicity-
dc.subjectorganoleptic property-
dc.subjectosteoporosis-
dc.subjectreview-
dc.subjectrheumatoid arthritis-
dc.subjectstructure activity relation-
dc.subjectstructure analysis-
dc.subjecttuberculosis-
dc.subjectulcerative colitis-
dc.subjectAnimals-
dc.subjectAntibodies-
dc.subjectDrug Carriers-
dc.subjectDrug Delivery Systems-
dc.subjectDrug Design-
dc.subjectGene Therapy-
dc.subjectHumans-
dc.subjectLectins-
dc.subjectMacromolecular Substances-
dc.subjectOsteoporosis-
dc.subjectProdrugs-
dc.subjectViruses-
dc.titleAdvances in prodrug designen
dc.typeoutro-
dc.contributor.institutionUniversidade Estadual Paulista (UNESP)-
dc.contributor.institutionUniversidade de São Paulo (USP)-
dc.description.affiliationLaboratório de Pesquisa e Desenvolvimento de Fármacos Departamento de Fármacos e Medicamentos UNESP, Araraquara-
dc.description.affiliationLaboratório de Planejamento e Síntese de Quimioterápicos Potencialmente Ativos Departamento de Farmácia USP/SP, São Paolo-
dc.description.affiliationUnespLaboratório de Pesquisa e Desenvolvimento de Fármacos Departamento de Fármacos e Medicamentos UNESP, Araraquara-
dc.identifier.doi10.2174/138955705774329528-
dc.identifier.wosWOS:000231837000003-
dc.rights.accessRightsAcesso restrito-
dc.relation.ispartofMini-Reviews in Medicinal Chemistry-
dc.identifier.scopus2-s2.0-24944549193-
Aparece nas coleções:Artigos, TCCs, Teses e Dissertações da Unesp

Não há nenhum arquivo associado com este item.
Mostrar item simples Mostrar item completo   Ver Estatísticas
 

Itens do Acervo digital da UNESP são protegidos por direitos autorais reservados a menos que seja expresso o contrário.